palivizumab
- CAS No.
- 188039-54-5
- Chemical Name:
- palivizumab
- Synonyms
- Synagis;palivizumab;Research Grade Palivizumab(DVV02801)
- CBNumber:
- CB11386500
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| storage temp. | Store at -20°C |
|---|---|
| FDA UNII | DQ448MW7KS |
| ATC code | J06BB16 |
palivizumab Chemical Properties,Uses,Production
Indications
Palivizumab (Synagis) is a humanized monoclonal antibody directed against the highly conserved A antigenic site of the F protein on the surface of RSV. It contains 95% human and 5% murine antibody sequences and tends to have little immunogenicity in humans. Palivizumab is composed of the human framework region of the IgG-1κ-chain joined to the antigen-binding regions of a mouse monoclonal antibody. Palivizumab neutralizes RSV and inhibits its ability to fuse with host cell membranes. Resistant strains of RSV have been derived in vitro but have not been found in clinical isolates to date.
Clinical Use
Palivizumab is used to prevent serious lower respiratory tract infection due to RSV. It is used only in high-risk children who are younger than 24 months of age and have bronchopulmonary dysplasia or chronic lung disease that required treatment in the previous 6 months. It is also indicated for premature infants (less than 32 weeks’ gestation) until the age of 6 to 12 months. Palivizumab can reduce the incidence of RSV-related hospitalization by approximately half.The safety and efficacy of palivizumab in the treatment of RSV disease have not been established.
Side effects
Serious adverse reactions caused by palivizumab are rare.Mild erythema and pain may occur at the injection site.Although no anaphylactoid reactions have been reported to date, the possibility of this reaction exists because palivizumab is a protein.
palivizumab Preparation Products And Raw materials
Raw materials
Preparation Products
palivizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2127 | 70 |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 | waley188@sohu.com | China | 12338 | 58 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9709 | 58 |
| ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 | 2853530910@QQ.com | China | 8018 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 15926423062 | 422450190@qq.com | China | 10132 | 58 |
| Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 | 2881924765@qq.com | China | 7980 | 58 |
| Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. | +86-027-59232304 15387063101 | 2881924050@qq.com | China | 9991 | 58 |
| AntibodySystem | 027-65279366 18162686757 | biolab-reagents@atagenix.com | China | 9784 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 13720134139 | orders@jknbiochem.com | China | 4952 | 58 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17721492509 | 643638326@qq.com | China | 5347 | 58 |